Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

[1]  Beth Wilmot,et al.  Functional Genomic Landscape of Acute Myeloid Leukemia , 2018, Nature.

[2]  Gregory W. Schwartz,et al.  Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia , 2017 .

[3]  J. Cortes,et al.  Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study , 2017 .

[4]  A. Olshen,et al.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. , 2017, Blood.

[5]  M. Levis,et al.  Midostaurin approved for FLT3-mutated AML. , 2017, Blood.

[6]  C. Bloomfield,et al.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.

[7]  M. Caligiuri,et al.  E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia , 2017, Leukemia.

[8]  M. Wong,et al.  FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. , 2016, Cancer research.

[9]  W. Hiddemann,et al.  Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. , 2016, Blood.

[10]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[11]  R. Collins,et al.  Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. , 2016 .

[12]  D. Muzny,et al.  Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. , 2016, Cancer research.

[13]  M. Akbari,et al.  Whole Exome Sequencing of Chronic Myeloid Leukemia Patients , 2016, Iranian journal of public health.

[14]  A. Ganser,et al.  Leukemogenic potency of the novel FLT3-N676K mutant , 2016, Annals of Hematology.

[15]  A. Lavrov,et al.  Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients , 2016, Leukemia & lymphoma.

[16]  R. Collins,et al.  Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib , 2015 .

[17]  R. Larson,et al.  Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study , 2015 .

[18]  S. Miyano,et al.  Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. , 2015, Blood.

[19]  A. Sali,et al.  FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors , 2015, Leukemia.

[20]  M. Konopleva,et al.  Secondary mutations as mediators of resistance to targeted therapy in leukemia. , 2015, Blood.

[21]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[22]  R. Larson,et al.  Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). , 2015 .

[23]  C. Mason,et al.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. , 2015, Cancer cell.

[24]  A. Kasarskis,et al.  Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. , 2015, Cancer discovery.

[25]  H. Kiyoi.  FLT3 INHIBITORS: RECENT ADVANCES AND PROBLEMS FOR CLINICAL APPLICATION , 2015, Nagoya journal of medical science.

[26]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[27]  Z. Estrov,et al.  Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations , 2014 .

[28]  M. Konopleva,et al.  Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations , 2014, Cancer.

[29]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[30]  M. Levis,et al.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond , 2014, Therapeutic advances in hematology.

[31]  J. Kuriyan,et al.  Crenolanib is a selective type I pan-FLT3 inhibitor , 2014, Proceedings of the National Academy of Sciences.

[32]  M. Levis,et al.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. , 2014, Blood.

[33]  S. Baker,et al.  Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. , 2013, Blood.

[34]  C. Eckert,et al.  Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. , 2013, Blood.

[35]  A. Kasarskis,et al.  Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML) , 2013 .

[36]  G. Martinelli,et al.  Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML) , 2013 .

[37]  Ryan J. Jacobs,et al.  Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer , 2013, PloS one.

[38]  S. Shurtleff,et al.  Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia , 2013, Clinical Cancer Research.

[39]  Jorge Cortes,et al.  Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. , 2013, Blood.

[40]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[41]  Catherine C. Smith,et al.  Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. , 2013, Blood.

[42]  Heng Li.  Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM , 2013, 1303.3997.

[43]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[44]  C. Peschel,et al.  The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib , 2013, Leukemia.

[45]  S. Lok,et al.  Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.

[46]  Andrew Kasarskis,et al.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.

[47]  J. Esteve,et al.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[49]  Jianxiang Wang,et al.  Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML. , 2012, Leukemia research.

[50]  P. Workman,et al.  Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns , 2012, Leukemia.

[51]  G. Habets,et al.  The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML, , 2011 .

[52]  M. Konopleva,et al.  p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. , 2011, Blood.

[53]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[54]  Daniel Rios,et al.  Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .

[55]  T. Haferlach,et al.  Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. , 2008, Blood.

[56]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[57]  T. Golub,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[58]  Kyu-Tae Kim,et al.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. , 2006, Blood.

[59]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[60]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[61]  R. Stone,et al.  Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. , 2006, Blood.